Further investigation of the cellular and molecular mechanisms of NET-mediated DA reuptake when DAT loss is at and beyond the degree associated with PD-associated motor symptoms could prove beneficial for locomotor capabilities in addition to providing a potential therapeutic target in the treatment of L-DOPA induced dyskinesia. Here, SLC6A3 is linked to drug-induced dyskinesia.